Algen Biotechnologies

algenbio.com →

+80%

est. 2Y upside i

HealthcareSeries D+

Using CRISPR to find treatments for cancer and inflammation

Rank

#909

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Algen represents a genuine high-optionality bet in a hot sector, meaningfully de-risked by the October 2025 AstraZeneca $555M partnership — but a candidate joining in May 2026 is entering at a post-announcement valuation that has already priced much of that catalyst.

Last updated: May 5, 2026

Bull (35%)+200%

The AstraZeneca partnership hits multiple early milestones, triggering $100M+ in payments and validating the AlgenBrain platform for additional pharma deals; Algen closes a Series B at a $400–500M post-money valuation. AstraZeneca or a competing pharma initiates acquisition discussions within 3 years, compressing the timeline and delivering a 3x+ return on current entry valuation.

Base (45%)+50%

The AZ partnership advances on schedule with modest milestone payments and research funding, supporting a Series B at roughly $250–300M — a moderate step-up from today's estimated $150–200M post-deal valuation. Common equity appreciates ~50% on paper but remains fully illiquid over the 2-year window, with a realistic exit still 3–5 years out.

Bear (20%)-65%

AZ partnership scopes down or encounters target-validation setbacks; Algen struggles to raise a Series B in a tightening biotech funding environment, forcing a down round at $75–100M that crushes common equity. The 14-person team faces runway pressure and key departures, eroding the AlgenBrain platform's competitive differentiation.

Est. time to liquidity~4.0 years

Preference Stack Risk

low

Funding Intensity

5%

$9.1M in total cumulative funding against an estimated post-AZ-partnership valuation of $150–200M implies a liquidation preference stack of roughly 5%, posing minimal overhang on common equity at any reasonable exit price above $20M.

Dilution Risk

high

Scaling from 14 to 100+ employees, funding a preclinical-to-clinical drug pipeline, and executing on AZ partnership deliverables will require $50–200M+ in future equity raises, meaning early common holders face multiple dilutive rounds before any exit.

Secondary Liquidity

none

At 14 employees and pre-revenue, Algen has no secondary market trading, no tender offers on record, and no realistic near-term liquidity outside a formal M&A or IPO event.

Questions to Ask at the Interview

Strategic questions based on Algen Biotechnologies's data — designed to show you've done your homework.

  • 1

    “What is the economic breakdown of the AstraZeneca $555M deal — specifically, how much was received as an upfront payment versus tied to preclinical, clinical, and commercial milestones, and what is the company's current cash runway?”

  • 2

    “Does the AstraZeneca partnership include any exclusivity provisions on therapeutic areas or target classes that would prevent Algen from signing additional pharma partnerships, and what is the pipeline strategy if AZ does not exercise downstream options?”

  • 3

    “What is the current 409A valuation and the post-money valuation from the March 2025 Later Stage VC round, and what are the liquidation preference terms — participating vs. non-participating — on the preferred stack relative to common equity?”

Community

Valuation Sentiment

Our model estimates +80% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.